SCHEMBL4592455

SCHEMBL4592455

CCc1c(Cl)cc(NC(C)c2ncc[nH]2)c(CC)c1NC(=O)N(Cc1ccc(OC)cc1)c1ccc(C(C)C)cc1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.36
TP53 P04637 4/20 0.36
MAPT P10636 1/20 0.36
FPR2 P25090 1/20 0.35
C5AR1 P21730 2/20 0.34
CYP3A4 P08684 1/20 0.34
GPR183 P32249 1/20 0.34
ADGRF1 Q5T601 1/20 0.34
GPR65 Q8IYL9 1/20 0.34
BCL2A1 Q16548 2/20 0.34
NR3C1 P04150 1/20 0.34
POLB P06746 2/20 0.33
GAA P10253 1/20 0.33
BMP1 P13497 2/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
NPBWR1 P48145 1/20 0.33
RNF4 P78317 1/20 0.32
CACNA1H O95180 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4592821 0.81 C5AR1 (0.38) SMN1; SMN2TP53MAPTC5AR1CYP3A4
SCHEMBL4592567 0.80 C5AR1 (0.38) SMN1; SMN2TP53MAPTC5AR1CYP3A4
SCHEMBL5049239 0.80 BCL2A1 (0.41) SMN1; SMN2TP53MAPTC5AR1CYP3A4
SCHEMBL4592145 0.80 BCL2A1 (0.41) SMN1; SMN2TP53MAPTC5AR1CYP3A4
SCHEMBL4592040 0.80 C5AR1 (0.39) SMN1; SMN2TP53MAPTC5AR1CYP3A4
SCHEMBL4592452 0.79 SMN1; SMN2 (0.36) SMN1; SMN2TP53MAPTC5AR1CYP3A4
SCHEMBL5154118 0.78 C5AR1 (0.36) SMN1; SMN2TP53MAPTC5AR1CYP3A4
SCHEMBL12047957 0.77 ALDH1A1 (0.44) SMN1; SMN2TP53MAPTC5AR1CYP3A4
SCHEMBL5050220 0.77 BCL2A1 (0.43) SMN1; SMN2TP53MAPTC5AR1GPR183
SCHEMBL4592666 0.77 APP (0.41) SMN1; SMN2TP53MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080220003-A1 C5a Receptor Antagonists JERINI AG (DE) 2008-09-11 US claimed
EP-1885691-A1 C5A RECEPTOR ANTAGONISTS Jerini AG (DE) 2008-02-13 EP claimed
WO-2006128670-A1 C5A RECEPTOR ANTAGONISTS JERINI AG (DE) 2006-12-07 WO claimed
US-8071810-B2 3-(3-Amino-2,6-diisopropyl-phenyl)-1-(4-isopropyl-phenyl)-1-(4-methoxy-benzyl)-urea; autoimmune disorders; inflammation JERINI AG (DE) 2011-12-06 US disclosed
US-20080220003-A1 C5a Receptor Antagonists JERINI AG (DE) 2008-09-11 US disclosed
EP-1885691-A1 C5A RECEPTOR ANTAGONISTS Jerini AG (DE) 2008-02-13 EP disclosed
WO-2006128670-A1 C5A RECEPTOR ANTAGONISTS JERINI AG (DE) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080220003-A1 C5a Receptor Antagonists C3AR1, C5AR2, C5AR1 SMN1; SMN2 4617/4885TP53 4032/4885MAPT 4871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.